Organisation paid for research Program year 2025 Source: CMS Open Payments

113 Efficient Services

Neither a doctor nor a teaching hospital

Research payments

$1,145,415

24 payments

Through program year 2025, 113 Efficient Services is reported as receiving $1,145,415 in research payments, across 24 payments.

By program year

3 rows

Year	Kind	Amount	Payments
2025	Research	$565,664	9
2024	Research	$412,948	8
2023	Research	$166,803	7

Breakdown

Who paid Research payments · program years 2023–2025

Eli Lilly and Company $1,145,415 24 payments

Studies the money was for Research payments · program years 2023–2025

A Phase 2B, Double-Blind, Placebo-Controlled Study to Evaluate Eltrekibart in Adult Participants With Moderate to Severe Hidradenitis Suppurativa $479,412 2 payments
Efficacy and Safety of Ixekizumab Or Ixekizumab Concomitantly Administered With Tirzepatide in Adult Participants With Moderate-To-Severe Plaque Psoriasis and Obesity Or Overweight: A Phase 3B, Randomized, Multicenter, Open-Label Study (Together-Pso) $116,756 1 payment
A Long-Term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-To-Severe Atopic Dermatitis $86,996 1 payment
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose Ranging Study of Ly4100511 (Dc-853) for the Treatment of Adult Participants With Moderate-To Severe Plaque Psoriasis $82,689 1 payment
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Lebrikizumab in Adult and Adolescent Participants With Moderate-To-Severe Atopic Hand and Foot Dermatitis $80,510 1 payment
A Phase 3, Multicenter, Long-Term Extension Study to Assess the Safety and Efficacy of Lebrikizumab in Participants 6 Months to <18 Years of Age With Moderate-To-Severe Atopic Dermatitis $79,620 2 payments
A Long-Term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-To-Severe Atopic Dermatitis $42,039 2 payments
An Open-Label, Study to Evaluate the Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participants With Moderate-To-Severe Atopic Dermatitis Previously Treated With Dupilumab $38,254 2 payments
A Multicenter Randomized Double-Blind Placebo-Controlled Phase 2 Study to Evaluate the Efficacy and Safety of Ly3041658 in Adults With Moderate-To-Severe Hidradenitis Suppurativa $25,518 1 payment
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy, Safety and Pharmacokinetics of Lebrikizumab Compared to Placebo in Participants 6 Months to <18 Years of Age With Moderate-To-Severe Atopic Dermatitis $23,625 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.